Manufacturing innovation is essential for monoclonal antibody affordability and access
Bibliographic record
Abstract
No abstract is available for this record. The assistant can identify its topic from the title, but cannot infer the study’s results.
Source: Not provided · Quality: missing
Research context
OpenAlex topics: Monoclonal and Polyclonal Antibodies Research · CAR-T cell therapy research · Protein purification and stability
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (19)
Show source-provided references
1. Pantaleo, G., Correia, B., Fenwick, C., Joo, V. S. & Perez, L. Antibodies to combat viral infections: development strategies and progress. Nat. Rev. Drug Discov. 21, 676–696 (2022).10.1038/s41573-022-00495-3 ↗
2. Gieber, L. et al. Access to monoclonal antibodies in Africa: A call to action (IAVI and Impact Global Health, 2024).
3. Expanding access to monoclonal antibody-based products: a global call to action (Wellcome and IAVI, 2020).
4. Rathore, A. S., Gardner, P. J., Chhabra, H. & Raman, R. Global outlook on affordability of biotherapeutic drugs. Ann. N. Y. Acad. Sci. 1537, 168–178 (2024).10.1111/nyas.15171 ↗
5. Khan, T., Abimbola, S., Kyobutungi, C. & Pai, M. How we classify countries and people-and why it matters. BMJ Glob. Health 7, e009704 (2022).10.1136/bmjgh-2022-009704 ↗
6. Okell, L. C. et al. Projected health impact of post-discharge malaria chemoprevention among children with severe malarial anaemia in Africa. Nat. Commun. 14, 402 (2023).10.1038/s41467-023-35939-w ↗
7. Kelley, B. The history and potential future of monoclonal antibody therapeutics development and manufacturing in four eras. MAbs 16, 2373330 (2024).10.1080/19420862.2024.2373330 ↗
8. Chen, C., Garcia, Z., Chen, D., Liu, H. & Trelstad, P. Cost and supply considerations for antibody therapeutics. MAbs 17, 2451789 (2025).10.1080/19420862.2025.2451789 ↗
9. Malhotra, S. et al. Novel approaches to enable equitable access to monoclonal antibodies in low- and middle-income countries. PLOS Glob. Public Health 4, e0003418 (2024).10.1371/journal.pgph.0003418 ↗
10. Garcia, F. A. & Gefroh, E. Reducing biopharmaceutical manufacturing costs through continuous processing in a flexible J.POD® facility. Drug Discov. Today 28, 103619 (2023).10.1016/j.drudis.2023.103619 ↗
11. Rathore, A. & Shereef, F. Innovating manufacturing technology in emerging economies. Nat. Biotechnol. 40, 1714–1716 (2022).10.1038/s41587-022-01499-5 ↗
12. Brady, J. R. & Love, J. C. Alternative hosts as the missing link for equitable therapeutic protein production. Nat. Biotechnol. 39, 404–407 (2021).10.1038/s41587-021-00884-w ↗
13. Chhiba, V. et al. South Africa’s indigenous microbial diversity for industrial applications: A review of the current status and opportunities. Heliyon 9, e16723 (2023).10.1016/j.heliyon.2023.e16723 ↗
14. Mahal, H., Branton, H. & Farid, S. S. End-to-end continuous bioprocessing: impact on facility design, cost of goods, and cost of development for monoclonal antibodies. Biotechnol. Bioeng. 118, 3468–3485 (2021).10.1002/bit.27774 ↗
15. Clinical research landscape of monoclonal antibodies: report on 2014-2023 period (WHO, 2025).
16. Rio de Janeiro declaration of the G20 health ministers (G20, 2024).
17. G-FINDER data portal: tracking funding for global health R&D (Impact Global Health, accessed 6 January 2025); https://gfinderdata.impactglobalhealth.org/.
18. Machingaidze, S. et al. The case for a global therapeutics development coalition: Building a therapeutics pipeline for pandemic and endemic diseases. PLOS Glob. Public Health 4, e0003654 (2024).10.1371/journal.pgph.0003654 ↗
19. Skingsley, A. & Baker, C. 100 Days Mission Therapeutics roadmap (IPPS, 2024).